Agilent Unveils Next‑Gen Lab Technologies to Boost India’s Testing Efficiency and Compliance

India's pharmaceutical, food, environmental and industrial testing laboratories are under increasing pressure to process higher testing volumes while maintaining quality, compliance and operational efficiency. From safeguarding the quality of medicines and food to supporting environmental monitoring and advanced manufacturing, laboratories are expected to deliver reliable results faster while meeting increasingly stringent quality and regulatory requirements.

To help laboratories meet these challenges, Agilent Technologies today announced the India launch of the Agilent 9500 Triple Quadrupole ICP-MS, the new 8890B and 8860B Gas Chromatography Systems with GC Assist, and OpenLab Sync, Agilent's new Lab Execution System (LES) that brings guided digital workflows directly to the bench.

“India's laboratories play a critical role in ensuring the quality of medicines, food, water and manufactured products that people rely on every day,” said Nandakumar Kalathil, Country General Manager, India, Agilent Technologies. “As testing requirements continue to grow across industries, laboratories are looking for ways to improve productivity without compromising quality. These new technologies are designed to make advanced capabilities easier to adopt while helping laboratories operate more efficiently and grow with confidence.”

Together, the solutions address three critical areas of laboratory operations: analytical performance, instrument productivity and workflow execution.

The Agilent 9500 Triple Quadrupole ICP-MS helps laboratories generate reliable results across complex sample matrices. Designed for applications ranging from pharmaceutical testing and food safety to environmental analysis and advanced materials research, the system simplifies elemental analysis through new technologies that reduce analytical interferences and streamline operation.

The new Agilent 8890B and 8860B Gas Chromatography Systems with GC Assist help laboratories keep instruments running efficiently through built-in monitoring, diagnostics and guided maintenance. By identifying potential issues earlier and simplifying routine upkeep, the systems help reduce downtime, improve productivity and support data quality.

OpenLab Sync digitizes laboratory procedures that are traditionally managed on paper, creating guided digital workflows that improve consistency, traceability and audit readiness. The solution helps laboratories standardize operations, reduce manual processes and address workforce and training challenges.

The products were unveiled today at a customer event in Mumbai that brought together scientists, laboratory leaders and quality professionals from the pharmaceutical, food, environmental, chemicals and research sectors. Mike Zhang, President, Applied Markets Group, Agilent Technologies, and Bharat Bhardwaj, Vice President and General Manager, Asia Pacific, Agilent Technologies, joined customers and industry stakeholders to discuss evolving laboratory needs, workforce trends, and opportunities to make advanced analytical capabilities more accessible to a broader range of users.

“Innovation has the greatest impact when it makes life simpler,” said Bharat Bhardwaj, Vice President and General Manager, Asia Pacific, Agilent Technologies. “The pace of science continues to accelerate, and customers want solutions that help them spend less time managing complexity and more time focusing on scientific discovery. Our goal is to help laboratories unlock the full value of their technology investments so they can focus on delivering meaningful scientific outcomes.”

The new products are now available across India. As part of its ongoing efforts to make support and expertise more accessible, Agilent has also introduced WhatsApp for Business in India, providing customers with an additional channel to connect with Agilent for information, service and support.

About Agilent Technologies

Agilent Technologies, Inc. (NYSE: A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers’ most challenging questions. The company generated revenue of $6.95 billion in fiscal year 2025 and employs approximately 18,000 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn and Facebook.

Agilent and Veeda Lifesciences Launch Joint Analytical CoE to Accelerate GLP‑1 and Complex Biologics Development Services

Agilent Technologies, a global leader in analytical and laboratory solutions, today announced a strategic collaboration with Veeda Lifesciences to strengthen regulatory‑aligned analytical and bioanalytical workflows supporting biopharma development, as GLP‑1 and other complex therapeutic modalities continue to advance rapidly through global pipelines.

The collaboration brings together Agilent’s expertise in analytical workflow development with Veeda’s established bioanalytical, clinical research and regulatory capabilities, with the objective of enabling high‑quality, inspection‑ready analytical data across early development, clinical, and manufacturing stages. Together, the two organizations aim to support biopharma companies navigating increasingly complex regulatory and data expectations for next‑generation therapies.

Central to the collaboration is the establishment of a joint Center of Excellence (CoE) at Veeda’s biopharma facility in Bengaluru. Designed as a scalable analytics and regulatory‑readiness hub, the CoE will focus on the development and validation of end‑to‑end analytical workflows. The CoE will address the growing analytical demands associated with next‑generation therapies, including GLP‑1 based drugs - where sensitivity, throughput, and data integrity are critical to support regulatory confidence and program progression.

“As GLP‑1 and other complex therapies move rapidly through development, the need for robust, regulatory‑aligned analytics becomes increasingly critical,” said Nandakumar Kalathil, Country General Manager, Agilent India. “Through our collaboration with Veeda, we aim to support biopharma organizations with workflow‑driven analytical approaches that strengthen data quality, compliance, and confidence across the development lifecycle.”

“As Biopharma innovation accelerates across the region, the need for integrated, regulatory ready analytical ecosystems is becoming increasingly critical,” said Bharat Bhardwaj, Vice President and General Manager, Asia Pacific, Agilent Technologies. “This collaboration between Agilent and Veeda Lifesciences reflects our commitment to enabling customers with advanced, scalable solutions that support confident decision-making across the drug development lifecycle, while Asia Pacific’s role as a hub for high quality- globally relevant biopharma research.”

“Biopharma companies today require analytical capabilities that are inspection‑ready from the outset,” said Mr. Binoy Gardi, Group CEO and Managing Director, Veeda Lifesciences. “By collaborating with Agilent, we are strengthening our ability to deliver integrated, regulatory‑aligned analytical workflows that support faster decision‑making and smoother progression from early development through clinical and manufacturing stages.”

Dr. Sanjib Banerjee, Chief Operating Officer (COO), Biopharma at Veeda Lifesciences, added, “This expansion of our service portfolio establishes an advanced, technology‑driven platform for the structural analytical characterization of complex biologics—including peptides (GLP-1), monoclonal antibodies, antibody–drug conjugates (ADCs) and other therapeutic proteins. Built on Veeda’s established capabilities in in depth proteomics, glycoproteomic and process‑related impurities analysis, and leveraging Agilent’s high-end Mass Spectrometry, this creates an integrated, regulatory‑aligned analytical ecosystem under one roof.”

By combining Agilent’s high-performance mass spectrometry with Veeda’s integrated bioanalytical and clinical research infrastructure, the partnership aims to extend services to sponsors across an expanding range of next-generation modalities with consistent, inspection-ready datasets. The initiative underscores Agilent and Veeda’s commitment to expand India’s high-end biopharma research infrastructure, while reinforcing India’s role as a trusted destination for advanced, globally aligned biopharma development.

About Agilent Technologies

Agilent Technologies, Inc. (NYSE: A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.95 billion in fiscal year 2025 and employs approximately 18,000 people worldwide. Information about Agilent is available at www.agilent.com.

About Veeda Lifesciences

Veeda Lifesciences is a leading independent contract research organization (CRO) offering comprehensive clinical, preclinical and bioanalytical services to support the development of innovative, biosimilar, and generic drugs. With state-of-the-art facilities in India and a strong focus on quality, and scientific excellence, Veeda partners with global pharmaceutical and biotech companies to accelerate product development and regulatory approvals.

Agilent and C‑CAMP Expand Collaboration to Boost India’s Biopharma Research Infrastructure

Agilent Technologies, a global leader in analytical and laboratory solutions, today announced an expansion of its collaboration with the Centre for Cellular and Molecular Platforms (C‑CAMP), a Department of Biotechnology supported initiative. The expanded engagement broadens access to advanced analytical and mass spectrometry‑based capabilities that support life sciences and therapeutic research across India.

Through this collaboration, high‑resolution analytical platforms will be made available via C‑CAMP’s shared infrastructure, supporting applications such as biotherapeutic characterization, oligonucleotide research, and quantitative biomolecular analysis. The model Agilent Technologies, a global leader in analytical and laboratory solutions, today announced an expansion of its collaboration with the Centre for Cellular and Molecular Platforms (C‑CAMP), a Department of Biotechnology supported initiative. The expanded engagement broadens access to advanced analytical and mass spectrometry‑based capabilities that support life sciences and therapeutic research across India. designed to enable researchers from startups, academia and industry to access advanced analytical workflows and deep domain expertise without the need for direct capital investment in specialized instruments or facilities.

As India continues to strengthen its focus on translational research and the development of advanced therapeutics, access to high‑quality analytical infrastructure has become increasingly critical. By expanding this collaboration, Agilent and C‑CAMP aim to help reduce entry barriers and support reliable, reproducible science across the research‑to‑development continuum.

Agilent’s collaboration with C‑CAMP has played a catalytic role in advancing India’s biopharma ecosystem by enabling world‑class, regulatory‑aligned characterization of biologics and biosimilars across therapeutic applications. Building on this momentum, the expanded collaboration deepens Agilent and C‑CAMP’s shared commitment to accelerating next‑generation biotherapeutics and reinforcing India’s ambition to emerge as a globally competitive biopharma hub.

The engagement aligns with C‑CAMP’s vision towards building a connected ecosystem that supports science‑to‑impact pathways, while leveraging Agilent’s expertise in analytical workflows and technology enablement.

“India is a strategic priority for Agilent, and partnerships like this are central to how we expand access to critical scientific capabilities,” said Nandakumar Kalathil, Country General Manager, Agilent India. “Working with C‑CAMP allows a broader community of researchers to leverage advanced analytical workflows that support high‑quality, reproducible science across discovery and translational research.”

“Across Asia Pacific, we are seeing a strong shift toward collaborative, shared infrastructure models that enable broader participation in advanced scientific research,” said Bharat Bhardwaj, Vice President and General Manager, Asia Pacific, Agilent Technologies. “Our expanded engagement with C CAMP reflects Agilent’s commitment to building inclusive innovation ecosystems—where startups, academia, and industry can accelerate high quality research and translate science into meaningful impact.”

“Partnerships with frontier science and technology leaders such as Agilent will help C-CAMP build cutting-edge capabilities in India to support researchers and innovators across the country. In the coming years, we believe such collaborations will play a key role in enabling technology development and accelerating science-led innovation,” said Dr Taslimarif Saiyed, Director and CEO, C‑CAMP. “The engagement also aligns with C-CAMP’s vision of building a connected ecosystem that supports science-to-impact pathways, while leveraging Agilent’s expertise in analytical workflows and technology enablement.”

The expanded collaboration reflects Agilent’s continued commitment to supporting India’s life sciences landscape by enabling scalable access to advanced analytical capabilities through trusted shared platforms.

Agilent Technologies, Inc. (NYSE: A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.95 billion in fiscal year 2025 and employs approximately 18,000 people worldwide. Information about Agilent is available at www.agilent.com.